Developmental regulation of the inhibitory effect of dopamine on prolactin release in the preterm neonate

Istvan Seri, Zsolt Somogyvari, Sarolta Hovanyovszky, Janos Kiszel, T. Tulassay

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The secretion and release of prolactin from the anterior pituitary is under the tonic inhibitory control of endogenous dopamine produced in the central nervous system. Exogenous dopamine inhibits prolactin secretion by reaching the pituitary via the portal circulation, and the hypolactotropic effect of dopamine infusion has been documented in all age groups in humans. However, the maturation of lactotroph sensitivity to dopaminergic inhibition has not been studied. Therefore, we followed the changes in serum prolactin concentrations before, during, and after dopamine infusion in 19 sick preterm infants with a mean gestational age of 30.6 ± 0.6 weeks during the first 3 days of life, and examined the relationship of the hypolactotropic effect of dopamine to gestational age and birth weight in this patient population. As expected, dopamine therapy resulted in a decrease in mean serum prolactin from 89.4 ± 9.5 to 58.6 ± 9.1 μg/l (p <0.05) with a return of the serum prolactin concentration to the pretreatment level 2-6 h after discontinuation of drug administration (98.3 ± 11.7 μg/l, p <0.05). However, simple regression analysis of the individual data revealed that the magnitude of the dopamine-induced decrease in serum prolactin was significantly influenced by gestational age (p = 0.006) and birthweight (p = 0.037). Thus, our findings provide evidence for the maturation of pituitary lactotroph sensitivity to dopaminergic inhibition in the preterm human neonate.

Original languageEnglish
Pages (from-to)137-144
Number of pages8
JournalBiology of the Neonate
Volume73
Issue number3
DOIs
Publication statusPublished - Mar 1998

Fingerprint

Prolactin
Dopamine
Newborn Infant
Lactotrophs
Gestational Age
Serum
Birth Weight
Premature Infants
Central Nervous System
Age Groups
Regression Analysis
Pharmaceutical Preparations
Population

Keywords

  • Dopamine
  • Pituitary
  • Preterm neonate
  • Prolactin

ASJC Scopus subject areas

  • Developmental Biology
  • Pediatrics, Perinatology, and Child Health

Cite this

Developmental regulation of the inhibitory effect of dopamine on prolactin release in the preterm neonate. / Seri, Istvan; Somogyvari, Zsolt; Hovanyovszky, Sarolta; Kiszel, Janos; Tulassay, T.

In: Biology of the Neonate, Vol. 73, No. 3, 03.1998, p. 137-144.

Research output: Contribution to journalArticle

Seri, Istvan ; Somogyvari, Zsolt ; Hovanyovszky, Sarolta ; Kiszel, Janos ; Tulassay, T. / Developmental regulation of the inhibitory effect of dopamine on prolactin release in the preterm neonate. In: Biology of the Neonate. 1998 ; Vol. 73, No. 3. pp. 137-144.
@article{35bc400494c4472d8ebf94ce8423fefc,
title = "Developmental regulation of the inhibitory effect of dopamine on prolactin release in the preterm neonate",
abstract = "The secretion and release of prolactin from the anterior pituitary is under the tonic inhibitory control of endogenous dopamine produced in the central nervous system. Exogenous dopamine inhibits prolactin secretion by reaching the pituitary via the portal circulation, and the hypolactotropic effect of dopamine infusion has been documented in all age groups in humans. However, the maturation of lactotroph sensitivity to dopaminergic inhibition has not been studied. Therefore, we followed the changes in serum prolactin concentrations before, during, and after dopamine infusion in 19 sick preterm infants with a mean gestational age of 30.6 ± 0.6 weeks during the first 3 days of life, and examined the relationship of the hypolactotropic effect of dopamine to gestational age and birth weight in this patient population. As expected, dopamine therapy resulted in a decrease in mean serum prolactin from 89.4 ± 9.5 to 58.6 ± 9.1 μg/l (p <0.05) with a return of the serum prolactin concentration to the pretreatment level 2-6 h after discontinuation of drug administration (98.3 ± 11.7 μg/l, p <0.05). However, simple regression analysis of the individual data revealed that the magnitude of the dopamine-induced decrease in serum prolactin was significantly influenced by gestational age (p = 0.006) and birthweight (p = 0.037). Thus, our findings provide evidence for the maturation of pituitary lactotroph sensitivity to dopaminergic inhibition in the preterm human neonate.",
keywords = "Dopamine, Pituitary, Preterm neonate, Prolactin",
author = "Istvan Seri and Zsolt Somogyvari and Sarolta Hovanyovszky and Janos Kiszel and T. Tulassay",
year = "1998",
month = "3",
doi = "10.1159/000013970",
language = "English",
volume = "73",
pages = "137--144",
journal = "Neonatology",
issn = "1661-7800",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Developmental regulation of the inhibitory effect of dopamine on prolactin release in the preterm neonate

AU - Seri, Istvan

AU - Somogyvari, Zsolt

AU - Hovanyovszky, Sarolta

AU - Kiszel, Janos

AU - Tulassay, T.

PY - 1998/3

Y1 - 1998/3

N2 - The secretion and release of prolactin from the anterior pituitary is under the tonic inhibitory control of endogenous dopamine produced in the central nervous system. Exogenous dopamine inhibits prolactin secretion by reaching the pituitary via the portal circulation, and the hypolactotropic effect of dopamine infusion has been documented in all age groups in humans. However, the maturation of lactotroph sensitivity to dopaminergic inhibition has not been studied. Therefore, we followed the changes in serum prolactin concentrations before, during, and after dopamine infusion in 19 sick preterm infants with a mean gestational age of 30.6 ± 0.6 weeks during the first 3 days of life, and examined the relationship of the hypolactotropic effect of dopamine to gestational age and birth weight in this patient population. As expected, dopamine therapy resulted in a decrease in mean serum prolactin from 89.4 ± 9.5 to 58.6 ± 9.1 μg/l (p <0.05) with a return of the serum prolactin concentration to the pretreatment level 2-6 h after discontinuation of drug administration (98.3 ± 11.7 μg/l, p <0.05). However, simple regression analysis of the individual data revealed that the magnitude of the dopamine-induced decrease in serum prolactin was significantly influenced by gestational age (p = 0.006) and birthweight (p = 0.037). Thus, our findings provide evidence for the maturation of pituitary lactotroph sensitivity to dopaminergic inhibition in the preterm human neonate.

AB - The secretion and release of prolactin from the anterior pituitary is under the tonic inhibitory control of endogenous dopamine produced in the central nervous system. Exogenous dopamine inhibits prolactin secretion by reaching the pituitary via the portal circulation, and the hypolactotropic effect of dopamine infusion has been documented in all age groups in humans. However, the maturation of lactotroph sensitivity to dopaminergic inhibition has not been studied. Therefore, we followed the changes in serum prolactin concentrations before, during, and after dopamine infusion in 19 sick preterm infants with a mean gestational age of 30.6 ± 0.6 weeks during the first 3 days of life, and examined the relationship of the hypolactotropic effect of dopamine to gestational age and birth weight in this patient population. As expected, dopamine therapy resulted in a decrease in mean serum prolactin from 89.4 ± 9.5 to 58.6 ± 9.1 μg/l (p <0.05) with a return of the serum prolactin concentration to the pretreatment level 2-6 h after discontinuation of drug administration (98.3 ± 11.7 μg/l, p <0.05). However, simple regression analysis of the individual data revealed that the magnitude of the dopamine-induced decrease in serum prolactin was significantly influenced by gestational age (p = 0.006) and birthweight (p = 0.037). Thus, our findings provide evidence for the maturation of pituitary lactotroph sensitivity to dopaminergic inhibition in the preterm human neonate.

KW - Dopamine

KW - Pituitary

KW - Preterm neonate

KW - Prolactin

UR - http://www.scopus.com/inward/record.url?scp=0031917680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031917680&partnerID=8YFLogxK

U2 - 10.1159/000013970

DO - 10.1159/000013970

M3 - Article

C2 - 9535530

AN - SCOPUS:0031917680

VL - 73

SP - 137

EP - 144

JO - Neonatology

JF - Neonatology

SN - 1661-7800

IS - 3

ER -